Tol Trimborn

Venture Partner

2016 - 2024

Chief Executive Officer

2020 - 2023

COO

2015 - 2020

Gadeta B.V. is a Research & Development company established in 2015, which focusses on the development of innovative immunotherapies for cancer. The work of the company is based on the groundbreaking discoveries regarding the role of γδ T cell receptors (TCR’s) in the broad recognition of heamatological and solid tumour cells and their potential use for the treatment of advanced malignancies as discovered by Prof. Jürgen Kuball at the University Medical Centre Utrecht (UMCU), The Netherlands.

CEO

2008 - 2015

Voorzitter bestuur Gooilandschool

2010 - 2014

General manager

2006 - 2008

Director Corporate Development

2005 - 2006

Senior director commercial development

2006 - 2008

Associate

2001 - 2005